

Resource Summary Report

Generated by [dkNET](#) on Sep 16, 2026

B6N.129S5(B6)-*Vsir*^{tm1Lex}/Mmucd

RRID:MMRRC_031656-UCD

Type: Organism

Proper Citation

RRID:MMRRC_031656-UCD

Organism Information

URL: https://www.mmrrc.org/catalog/sds.php?mmrrc_id=31656

Proper Citation: RRID:MMRRC_031656-UCD

Description: Mus musculus with name B6N.129S5(B6)-*Vsir*^{tm1Lex}/Mmucd from MMRRC.

Species: Mus musculus

Notes: Research areas: ; Mutation Type: Targeted Mutation ; Collection: Genentech

Phenotype: hepatic necrosis [MP:0001654]| abnormal T cell activation [MP:0001828]| increased inflammatory response [MP:0001846]| increased IgM level [MP:0002494]| increased IgA level [MP:0002495]| increased susceptibility to experimental autoimmune encephalomyelitis [MP:0004799]| increased tumor necrosis factor secretion [MP:0008560]| increased interferon-gamma secretion [MP:0008566]| increased interleukin-17 secretion [MP:0008681]| pancreas necrosis [MP:0009148]| pulmonary necrosis [MP:0010857]

Affected Gene: *Vsir*

Catalog Number: 031656-UCD

Background: Targeted Mutation

Database: Mutant Mouse Resource and Research Center (MMRRC)

Database Abbreviation: MMRRC

Source References: [PMID:20562862](#)

Alternate IDs: MMRRC_31656-UCD, MMRRC_031656, MMRRC_31656

Organism Name: B6N.129S5(B6)-*Vsir*^{tm1Lex}/Mmucd

Record Creation Time: 20230308T055124+0000

Ratings and Alerts

No rating or validation information has been found for B6N.129S5(B6)-*Vsir^{tm1Lex}*/Mmucd.

No alerts have been found for B6N.129S5(B6)-*Vsir^{tm1Lex}*/Mmucd.

Data and Source Information

Source: [Integrated Animals](#)

Source Database: Mutant Mouse Resource and Research Center (MMRRC)

Usage and Citation Metrics

We found 9 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#).

Gilmour C, et al. (2026) T cell-intrinsic VISTA expression promotes resistance to CTLA-4 blockade by restricting CD8+ T cell responses. The Journal of clinical investigation, 136(6).

Ta HM, et al. (2024) LRIG1 engages ligand VISTA and impairs tumor-specific CD8+ T cell responses. Science immunology, 9(95), eadi7418.

Zhang K, et al. (2024) VISTA promotes the metabolism and differentiation of myeloid-derived suppressor cells by STAT3 and polyamine-dependent mechanisms. Cell reports, 43(1), 113661.

EITanbouly MA, et al. (2020) VISTA is a checkpoint regulator for naïve T cell quiescence and peripheral tolerance. Science (New York, N.Y.), 367(6475).

Wang G, et al. (2020) The expression and immunoregulation of immune checkpoint molecule VISTA in autoimmune diseases and cancers. Cytokine & growth factor reviews, 52, 1.

Broughton TWK, et al. (2019) Defining the Signature of VISTA on Myeloid Cell Chemokine Responsiveness. Frontiers in immunology, 10, 2641.

Xu W, et al. (2019) Immune-Checkpoint Protein VISTA Regulates Antitumor Immunity by Controlling Myeloid Cell-Mediated Inflammation and Immunosuppression. Cancer immunology research, 7(9), 1497.

Wang L, et al. (2014) Disruption of the immune-checkpoint VISTA gene imparts a proinflammatory phenotype with predisposition to the development of autoimmunity. Proceedings of the National Academy of Sciences of the United States of America, 111(41), 14846.

Flies DB, et al. (2014) Coinhibitory receptor PD-1H preferentially suppresses CD4⁺ T cell-mediated immunity. *The Journal of clinical investigation*, 124(5), 1966.